This opportunity allows highly motivated students interested in orthopedics to be integrated into our academic orthopedics department for a year. You will be in constant conversation with faculty, residents, and department researchers as you learn the basics of research design, methodology, data analysis, and how to navigate the process from IRB application to manuscript submission. In addition to research, there are weekly opportunities for clinical exposure including surgery, clinic and department conferences. There are 3 tracks available: Basic Sciences, Pediatric Orthopedics, centered at the Children’s Hospital of New Orleans, and Adult Orthopedics, centered on the LSU medical school campus (however, all fellows will spend some time at each location).
A commitment for 1 academic year (fall to summer).
Develop and complete at least 2-3 independent research projects
Facilitate ongoing student/resident research projects where necessary.
Manage the content of research websites
Transporting research material, for example from operating theater to laboratories
Personal transportation required
Present your progress at monthly department research meetings
Attend weekly clinics and/or surgeries with various faculty members
Participate in the LSU Ortho student research committee
Participate in health disparities research (a department priority), including tissue bank projects, proposals, and grant submissions
Attend all department didactic/teaching sessions
Assist in developing/maintaining databases for surgical research
Effectively communicate the status of each project and progress with research team members
Select 1 of the 3 tracks (basic sciences, clinical adults/trauma, clinical pediatrics)
Full-time position, approximately $1150/month stipend
For more information please contact Dr. Vinod Dasa (This email address is being protected from spambots. You need JavaScript enabled to view it.) with regard to the orthopedic direction of adult and basic sciences or Dr. Carter Clement (This email address is being protected from spambots. You need JavaScript enabled to view it.) regarding pediatric orthopedics training.
CARLSBAD, Calif., Oct. 18, 2023 /PRNewswire/ — Advanced Biologics (commercially known as Biologica Technologies), a California-based company known for their innovative biological solutions, today announced their successful merger with Isto Biologics, a global leader in regenerative and autologous therapies.
The merger will seamlessly integrate Advanced Biologics’ proprietary products into Isto’s valued and growing portfolio of allografts within their Influx™ line.
“We are pleased that our entire Advanced Biologics/Biologica team will be joining forces with Isto Biologics,” said Amit Govil, president of Advanced Biologics. “This merger brings together the clinical, commercial and research-driven expertise of both companies and a shared commitment to helping patients heal faster.”
Advanced Biologics has maintained a commercial partnership with Isto Biologics since 2020, catalyzed by the development of Isto’s Integrative Bone Matrix, SPARC™. SPARC is a novel inductive bone matrix derived from Advanced Biologics’ proprietary tissue processing method used in their signature allograft, OsseoGen®. SPARC is known for its increased levels of osteoinductive, chemotactic, angiogenic and proliferative growth factors.
The integration of Advanced Biologics’ product commercialization initiatives into Isto’s growing allograft portfolio provides a unique opportunity to help patients heal faster and enable both customer bases to benefit from the broader product range.
“Over the past four years, our partnership with Advanced Biologics has been impressive,” said Harry Holiday, Chairman of the Board of Directors of Isto Biologics and Managing Director at Thompson Street Capital Partners (TSCP). “Investing in Advanced Biologics and entering into this strategic combination strengthens the extensive biologics portfolios of both Isto and Advanced Biologics, paving a path forward for continued growth and patient healing.”
“Through this merger, our combined team will now have greater clinical expertise and deeper customer support to provide our champion surgeons with the best products available in the market,” said Don Brown, CEO of Isto Biologics.
About Advanced Biologicals/Biologics Technologies
Advanced Biologics (ABC) is a three-way, Orthopedics this week – Prize for new technology winning biological company focused on developing innovative and clinically relevant biological solutions for a wide range of medical specialties. To better serve customers, Advanced Biologics formed Biologica Technologies in 2015 as a separate, standalone company that will serve as its sales, marketing and clinical research group. Advanced Biologics’ core technology provides the ability to access intracellular growth factors (GFs) found in allograft tissue. ProteiOS® Growth Factor and OsseoGEN® Cellular Bone Matrix are among the first products based on the technology and possess the highest concentration of GFs within their respective biological categories. The company is privately held and headquartered in Carlsbad, CA.
About Isto Biologics
Isto Biologics is a leading biologics and cellular therapy company in the orthopedic sector. Isto Biologics focuses on helping patients heal faster through innovative bone regeneration solutions and cell-based therapies. The company’s flagship product offerings include the market-leading Magellan® Autologous Platelet Separator and bone growth products, including InQu® Bone Graft Extender & Substitute, and the Influx™ product family.
Kettering Health is pleased to announce a partnership with Orthopedic Associates of SW Ohio and extend an invitation to ambitious individuals looking to improve their residency application and further develop their foundation in clinical research. Fourth-year medical students and graduate medical students (DO/MD applicants only) with an interest in orthopedic surgery are encouraged to apply for a funded clinical research fellowship in Dayton, Ohio.
Position: Orthopedic researcher
Duration: 12 months (July 2024 – July 2025)
Place: Kettering Health Campuses, Dayton, OH
Salary: 1099 Contract with Biweekly Allowance ($800/week or $1600/biweekly or $3200/month @ $38,400/year)
The goal of the Orthopedic Surgery Residency Program at Kettering Health is to develop competent, caring, versatile, practice-ready orthopedic surgeons. We focus on providing high-quality evidence-based treatment; the orthopedic assistants are involved in the coordination and delivery of that care during the educational experience. Residents are instructed by a host of dedicated general and fellowship-trained orthopedic clinical faculty, many of whom practice with Orthopedic Associates of SW Ohio.
The Orthopedic Research Fellow will work closely with clinical faculty and orthopedic residents as an Orthopedic Research Fellow. In all aspects of the orthopedic specialty, research fellows will be pioneers in the coordination and conduct of clinical orthopedic research examining a broad scope of general and subspecialty orthopedic surgery. The research fellow will have the opportunity to work with clinical faculty whose interests are similar to their own, as well as a wide range of sub-specialty orthopedic surgeons. Previous experience in academic or clinical research, particularly with previous peer-reviewed publications, is preferred but not required to apply. Consider submitting writing samples if this applies to your experience with your application. In addition to the experience gained in the field of clinical orthopedic research, the orthopedic researcher can expect to enhance their residency application with robust exposure to clinical orthopedics and orthopedic surgery, further develop research skills that will be important in their medical career, networks with orthopedic faculty and residents and may be able to demonstrate their own technical skills. The experience will be invaluable as they pursue a career in orthopedic surgery.
Responsibilities of research staff:
– Collaborate with industry to establish cadaver workshops for orthopedic implants and research
– Ambassador of Virtual Reality Training with Orthopedic Resident and Guidance with PrecisionOS
– Collaborate with orthopedic residents and faculty by organizing quarterly research meetings and overseeing all department clinical research projects.
– Create and evaluate clinical research questions, coordinate relevant literature searches and plan clinical trials
– Preparation of manuscripts, posters and oral presentations related to orthopedic clinical research
– Attend all relevant conferences, including the preparation of research abstracts, posters and presentations (registration and costs covered for activities related to research presentations at academic and clinical meetings across the country)
– Coordinating and managing orthopedic medicine interns during the summer period
– Educate patients and enroll them in research studies (may include calling and coordinating follow-up with patients).
– Some examinations require participation in a clinic and physical examination, as well as the use of specific equipment.
– Collaborate with the hospital clinical research team, EMR clarity team and IRB to ensure appropriate research oversight/integrity and patient safety.
– Collect, organize and analyze clinical data
– Maintain and develop relationships with industry partners to support research efforts
– Working closely with Dr. Brent Bamberger, orthopedic surgery program director and clinical orthopedic faculty.
Registration procedure:
– Interested applicants should apply to the Orthopedic Surgery Residency Program Coordinator, Machele Maus (This email address is being protected from spambots. You need JavaScript enabled to view it.), with the following:
– Declaration of interest (maximum one paragraph, 250 words or less)
WESTMINSTER, Colo., Oct. 17, 2023 /PRNewswire/ — Cerapedics Inc., a commercial-stage orthopedic company committed to redefining the standard of care for bone repair, today announced long-term follow-up data from its pivotal IDE study of i-FACTOR Peptide-Enhanced Bone Graft. Published data demonstrated single-level anterior cervical discectomy and fusion (ACDF) fusion rates of 98.6% after six years in patients treated with i-FACTOR and reinforce Cerapedics’ commitment to accumulating long-term clinical evidence. In particular, the results support the safety and efficacy profile of i-FACTOR at one and two years, as published in Spine And Neurosurgery.
i-FACTOR has demonstrated statistical superiority over local autograft in overall success* at one- and two-year endpoints for single-level ACDF. i-FACTOR further demonstrated spine fusion rates of 89.7%, 97.3% and 98.6% at one, two and six years, respectively, versus 85.8%, 95.8% and 97.3% for local autograft, with results published in Spine And Neurosurgery. 220 of the original 319 patients were observed for six years or 72 months.
The six-year results, published earlier this year in Neurosurgery, were based on a single-blinded, randomized, controlled prospective study of i-FACTOR compared to local autograft in single-level ACDF, which enrolled a total of 220 patients, including 106 in the i-FACTOR group and 114 in the local autograft control arm. Of the 22 locations from the original IO study, 17 participated in this six-year post-approval study.
“Physicians are looking for long-term safety and efficacy data to support decision-making about the safest and most effective spine technologies,” said Professor Paul Arnold, CARLE Illinois College of Medicine, principal investigator and author of the 12-, 24- and publications from 72 months. “In this unique long-term follow-up data from a pivotal IDE study, i-FACTOR met all four FDA-mandated non-inferiority success criteria and demonstrated safety and efficacy in single-level anterior cervical discectomy and fusion compared to autograft at 12 years of age age. , 24 and 72 months.”
“These results clearly demonstrate the efficacy rates and safety profile of i-FACTOR over time and also reflect Cerapedics’ commitment to producing the highest quality evidence on the use of our products,” said Valeska Schroeder, Chief Executive Officer of Cerapedics. “Combined with the results of the IDE study, these data contribute to the clinical understanding of the efficacy and safety of i-FACTOR. While there are numerous other bone grafting options, many have not undergone the same level of testing. This data has a significant impact on insurance payers looking for Level 1 evidence when making coverage decisions.”
i-FACTOR is available in the US through pre-market approval. It is the most stringent type of marketing application required by the FDA and involves the process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices based on Level 1 clinical trials. Cerapedics is currently conducting its second clinical randomized controlled trial for an indication for transforaminal lumbar interbody fusion (TLIF) involving 290 subjects, which is registered onclinicaltrials.gov.
About i-FACTOR Peptide-enhanced bone graft i-FACTOR is a Class III FDA-approved bone graft supported by rigorous Level 1 human clinical data from an IDE study published in Spine And Neurosurgery. It is the only spinal bone graft powered by P-15 osteogenic cell-binding peptide, with a precise bone-building mechanism.** i-FACTOR has a demonstrated safety profile and is as safe as local autograft in single-level ACDF with proven statistical superiority overall success* after one and two years.
i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for the reconstruction of a degenerated cervical intervertebral disc at one level from C3-C4 to C6-C7. i-FACTOR Peptide Enhanced Bone Graft should be used in an allograft bone ring and with additional anterior plate fixation. For more information, full description of the indication for use, contraindications, safety warnings etc. about i-FACTOR, please visit our website: https://www.cerapedics.com/sites/default/files/2023-08/40002 – 07-4%20Putty%20USA.pdf
About Cerapedia Cerapedics is a global commercial-stage orthopedic company that aims to redefine the standard of care for bone repair by healing bones faster and faster, without compromising safety, so patients can live their healthiest lives. Bone grafts, including Cerapedics products, are used in more than four million spine, orthopedics, trauma and interventional procedures worldwide each year. i-FACTOR is a Class III FDA-approved product indicated for single-level ACDF. Cerapedics’ new “P-15 Bone Graft” product is currently being evaluated for use in lumbar interbody fusion through ASPIRE, a pivotal clinical trial, and has received Breakthrough Device Designation from the FDA. Cerapedics is headquartered in Westminster, CO.
For more information, please visit us at www.cerapedics.com.
Media contact: Ten Bridge communications
TBCCerapedics@tenbridgecommunications.com
*Defined as meeting the Fusion, Function (Neck Disability Index), Neurological, and Safety endpoints
**Surface-based mode of action
This new position is intended for medical students who wish to strengthen their competitive position to obtain a residency position in the field of orthopedic surgery. Research assistants will work with national and international leaders in the field of total joint replacement to assist in preparing manuscripts for publication in peer-reviewed journals, to collect and analyze data, to attend and present your work at regional and national conferences, and to assist with FDA investigations of new drugs and devices. This is a large-scale research center where numerous projects have not only been published in PubMed-indexed journals, but have also been selected to present at national orthopedic meetings, namely the AAOS and AAHKS.
Research assistants have the opportunity to attend daily morning conferences at the orthopedic surgery residency, led by program director Dr. Jack Ingari, MD. This is an excellent opportunity to strengthen your resume and increase your chances of matching with an orthopedic surgery residency.
– Research into basic scientific and clinical aspects of total joint arthroplasty and preservation.
– Learn to create and extract clinical data from institutional and national databases
– Develop a better appreciation for biostatistics in the orthopedics setting
– Prepare manuscripts and textbook chapters.
– Present at research meetings, seminars, journal clubs, symposia and professional association meetings.
EDUCATIONAL LEVEL REQUIREMENT OR REASONS: All candidates who have completed their third year and passed their USMLE Step 1 and/or COMLEX Level 1 board exams. It is preferable that USMLE Step 2 be completed before beginning the research program. Experience in writing and biostatistics is a plus.
APPLICATION: Attach the following materials This email address is being protected from spambots. You need JavaScript enabled to view it.:
First combination of three clinically proven biomaterials now available for the manufacture of medical devices such as spinal and cardiovascular implants
FLOWOOD, Miss., Oct. 17, 2023 (GLOBE NEWSWIRE) — Superior Polymers, an innovator in advanced materials for medical applications, today announces the launch of Magnolia Trinity PEEK, which brings together three clinically proven biomaterials. Magnolia Trinity PEEK combines carbon fiber, hydroxyapatite and polyetheretherketone – three crucial materials needed in high-performance medical applications. Now Magnolia Trinity PEEK offers unparalleled versatility, biocompatibility and durability for medical devices such as orthopedic and cardiovascular implants or surgical instruments, catheter components and more.
“Superior Polymers pushed the boundaries of materials science to create Magnolia Trinity PEEK,” said Bob Fruge, director of Business Development for Superior Polymers. “Bringing these three proven materials together in one application is unprecedented. This new composite material opens up new possibilities for the use of implantable polymers for engineers, designers and manufacturers. We are thrilled to bring Magnolia Trinity PEEK to our customers and the marketplace to ultimately improve patient outcomes.”
Multiple studies have proven the positive effects of hydroxyapatite, carbon fiber and polyetheretherketone.i Carbon fiber is known for its exceptional mechanical properties, while hydroxyapatite is a natural mineral component of bone, known for its osteoconductive properties. By combining these materials, multifunctional composites can be created that can simultaneously provide structural support, promote bone growth and resist wear and tear.
Magnolia Trinity PEEK is easily machinable and can be easily customized to specific medical device designs. This versatility allows for the creation of complex and patient-specific implants.
Additional key features and benefits of Magnolia Trinity PEEK include:
Fatigue resistance: Carbon fiber reinforcement improves the fatigue resistance of PEEK.
Reduced wear and friction during joint replacement and prosthetics: High abrasion resistance and low friction properties due to the presence of carbon fiber are advantageous in applications involving hinged or sliding components, such as joint replacements and prosthetics.
Osteoconductive potential: Hydroxyapatite is a naturally occurring mineral found in bone and when combined with PEEK it improves the osteoconductive properties of the material.
Improved radiolucency: Carbon fibers improve radiolucency compared to pure PEEK, which is relatively radiopaque.
Better hemocompatibility: Higher crystallinity of the composite can cause less hemolysis and thrombin formation and reduce platelet adhesion, making it a promising material for cardiovascular applications.
Magnolia Trinity PEEK is available now. Visit superior-polymers.com today to schedule a consultation to learn more and explore its potential applications with a materials expert. Representatives from Superior Polymers will attend the upcoming annual North American Spine Society (NASS) event in Los Angeles, CA, October 18-21, 2023. To schedule a meeting, email Bob Fruge at bob.fruge@superior-polymers.com.
About superior polymers
Superior Polymers is a leading innovator in advanced materials, committed to delivering cutting-edge solutions to industries around the world. With a strong focus on customer service, our team of experts strives to create materials that exceed expectations in performance, durability and versatility. More information at www.superior-polymers.com.
Contact:
Email address: bob.fruge@superior-polymers.com
Phone number: 601-345-4515
Company website: http://www.superior-polymers.com
Social media links: https://www.linkedin.com/company/superior-polymers/
PR contact Melany Joy Beck | melany.beck@512financial.com Cell: (737) 900-7986
i https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987717/
https://pubmed.ncbi.nlm.nih.gov/25780341/
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c3d86fcc-172b-4d59-b90c-e983978048cf
